2024-03-28T20:33:40Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00019890
2022-12-15T03:50:46Z
453:456
471:537:538:1158
7)乳癌の自家骨髄移植療法(シンポジウム 自家骨髄移植の応用, 第482回新潟医学会)
7)乳癌の自家骨髄移植療法(シンポジウム 自家骨髄移植の応用, 第482回新潟医学会)
Dose Intensive Chemotherapy with Autologous Bone Marrow Transplantation in Breast Cancer (Application of Autologous BMT to Cancer Treatment)
田島, 知郎
autologous bone marrow transplantation
breast cancer chemotherapy
adjuvant chemotherapy
自家骨髄移植
乳癌化学療法
乳癌補助化学療法
Autologous bone marrow transplantation (ABMT) was first introduced in 1979, and by the end of 1991, 61 patients with recurrent/advanced breast cancer were treated with ABMT-supported chemotherapy, and their responses appeared superior to those obtained with conventional chemotherapy. Although there have been some prolonged disease-free survivors and some of them may have been actually cured, these cases have been exceptional. It was thus felt that ABMT-supported chemotherapy should also be applied for patients with mimimum tumor residue with no prior chemotherapy. 59 patients with alleged high risk for recurrence have been enrolled in adjuvant ABMT-supported chemotherapy trial, with the longest follow-up period being 137 months. There were 23 patients who had 10 or more positive lymphnodes, and they showed 38.5% 5 year relapse-free survival(RFS), which was in contrast to 10.0% in 30 patients treated with conventional postoperative adjuvant therapy. There were 10 patients who had been treated more than 5 years ago, and their 5 year RFS was 50.0% contrasting to 14.0% in 19 control patients. The chemotherapeutic regimen used in adjuvant was rather modest, since death is least acceptable in these situations.
新潟医学会
1993-09
jpn
departmental bulletin paper
http://hdl.handle.net/10191/37677
https://niigata-u.repo.nii.ac.jp/records/19890
AN00182415
00290440
新潟医学会雑誌
新潟医学会雑誌
107
9
815
820
https://niigata-u.repo.nii.ac.jp/record/19890/files/107(9)_815-820.pdf
application/pdf
1.3 MB
2019-08-16